A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2009
11/25/2009	EP2120923A1 Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
11/25/2009	EP2120921A2 Use of aminolevulinic acid and derivatives thereof
11/25/2009	EP2120920A2 Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
11/25/2009	EP2120919A1 New combination for use in the treatment of inflammatory disorders
11/25/2009	EP2120918A2 Pharmaceutical composition for treating incontinence
11/25/2009	EP2120916A1 Modulators of antigen-dependent t cell proliferation
11/25/2009	EP2120915A2 Polyelectrolyte precipitation and purification of antibodies
11/25/2009	EP2120914A1 Use of gentian violet in treatment of atopic dermatitis
11/25/2009	EP2120913A2 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
11/25/2009	EP2120912A1 Methods of correcting imbalance between bone resorption and bone formation and kits and compositions therefor
11/25/2009	EP2120911A1 Amide and urea derivatives for the treatment of metabolic diseases
11/25/2009	EP2120910A2 Heterocycle compounds and methods of use thereof
11/25/2009	EP2120909A2 Treatments of therapy-resistant diseases comprising drug combinations
11/25/2009	EP2120908A1 Solvating system and sealant for medical use
11/25/2009	EP2120907A1 Psychotropic compounds, compositions and methods of use
11/25/2009	EP2120905A1 Methods, compounds, and compositions for treating metabolic disorders and diabetes
11/25/2009	EP2120903A1 Antibacterial formulations
11/25/2009	EP2120900A2 Combination of lbh589 with other therapeutic agents for treating cancer
11/25/2009	EP2120898A1 Calcilytic compounds
11/25/2009	EP2120896A1 Medically active plaster
11/25/2009	EP2120889A1 Gelatin capsules comprising an acid
11/25/2009	EP2120888A1 Time- specific delayed/pulsatile release dosage forms
11/25/2009	EP2120887A1 Controlled-release preparation containing cilostazol and process for the preparation thereof
11/25/2009	EP2120886A2 Modified-release formulations of azabicyclo derivatives
11/25/2009	EP2120885A2 Solid preparation comprising 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-4-fluorobenzonitrile
11/25/2009	EP2120883A1 Pharmaceutical composition comprising a salt of rosiglitazone
11/25/2009	EP2120882A2 Pharmaceutical composition containing a cholesterol absorption inhibitor
11/25/2009	EP2120881A2 Method of determining the weight of the coating to be applied to form a controlled release dosage form
11/25/2009	EP2120880A2 Pellets comprising an active substance matrix resistant to gastric juice
11/25/2009	EP2120878A1 A dosage form containing two or more active pharmaceutical ingredients in different physical forms
11/25/2009	EP2120877A2 Imatinib mesylate
11/25/2009	EP2120875A1 Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
11/25/2009	EP2120873A1 Topical dosage form comprising tri-substituted glycerol compounds
11/25/2009	EP2120872A1 Nanoemulsion
11/25/2009	EP2120870A2 Terbinafine formulation for iontophoresis
11/25/2009	EP2120868A2 Low-dose mometasone formulations
11/25/2009	EP2120866A1 Pharmaceutical compositions for transmucusal delivery of a therapeutically active agent on the basis of submicron particles
11/25/2009	EP2120865A2 Method of producing a composition from an oleogel and an aqueous gel and the composition
11/25/2009	EP2120863A1 Pharmaceutical compositions based on a microemulsion
11/25/2009	EP2120858A2 Effervescent formulations of florfenicol for addition in drinking water systems
11/25/2009	EP2120855A2 Use of chroman-4-on-derivatives
11/25/2009	EP2120585A1 Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
11/25/2009	EP2120584A1 Silylated piperidine derivatives
11/25/2009	EP2120580A2 Compositions and methods for the treatment of metabolic disorders
11/25/2009	EP2120578A1 Kinase inhibitor compounds
11/25/2009	EP2120575A1 Sphingosine-1 -phosphate receptor agonist and antagonist compounds
11/25/2009	EP2120573A1 Piperidine derivatives
11/25/2009	EP2120571A1 Bifunctional active sites for adsorption of nox
11/25/2009	EP2120570A1 Treatment of comorbid premature ejaculation and erectile dysfunction
11/25/2009	EP2120569A2 Spirochromanon derivatives
11/25/2009	EP2120568A2 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
11/25/2009	EP2120567A1 Prodrugs of substituted 1,3-dioxanes and their uses
11/25/2009	EP2120564A1 Benzazepine compounds as cgrp receptor antagonists
11/25/2009	EP2120563A1 Compounds and uses thereof
11/25/2009	EP2120561A1 Compositions for treating biofilms and methods for using same
11/25/2009	EP2120557A2 Polyhydroquinoline compounds and dihydropyridine compounds for inhibiting beta-amyloid production
11/25/2009	EP2120555A1 Methods and compositions for the treatment of pain
11/25/2009	EP1963318B1 Pyrrolo[2,3-c]pyridine derivatives
11/25/2009	EP1924299B1 Ultra high molecular weight polyethylene articles and methods of forming ultra high molecular weight polyethylene articles
11/25/2009	EP1899331B1 Homomorpholine oxazolidinones as antibacterial agents
11/25/2009	EP1856050B1 Crystalline forms of a biphenyl compound
11/25/2009	EP1828172B1 Pyrrole derivatives having crth2 receptor antagonist activity
11/25/2009	EP1776099B1 Methods for improving bioavailability of a renin inhibitor
11/25/2009	EP1765335B1 Pyrazole amide derivatives, compositions containing such compounds and methods of use
11/25/2009	EP1691783B1 Pre-metered dry powder inhaler for moisture-sensitive medicaments
11/25/2009	EP1663398B1 Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors
11/25/2009	EP1618106B1 Carbacephem beta-lactam antibiotics
11/25/2009	EP1558595B1 Piperazinyl and diazapanyl benzamides and benzthioamides
11/25/2009	EP1537135B1 Adenosine a3 receptor agonists
11/25/2009	EP1482932B1 N3 alkylated benzimidazole derivatives as mek inhibitors
11/25/2009	EP1390041B1 Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
11/25/2009	EP1322299B1 Composition for the transdermal delivery of fentanyl
11/25/2009	EP1268509B1 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof
11/25/2009	EP1242385B1 Cytokine, especially tnf-alpha, inhibitors
11/25/2009	EP1210108B1 Use of leptin together with an inhibitor of vegf and/or an inhibitor of angiogenesis for the inhibition of endothelial cell proliferation
11/25/2009	EP1144405B1 Triazole compounds with dopamine-d3-receptor affinity
11/25/2009	EP1113797B1 Use of duloxetine for the treatment of fibromyalgia
11/25/2009	EP1017275B1 Polyamine treatment of neurological disorders
11/25/2009	EP0954585B1 Human telomerase reverse transcriptase promoter
11/25/2009	EP0931060B1 Substituted n- (aminoiminomethyl or aminomethyl)phenyl propyl amides
11/25/2009	CN101589309A Methods for screening and treatment involving the genes GYPC, AGPAT3, AGL, PVRL2, HMGB3, HSDL2 and/or LDB2
11/25/2009	CN101589064A Iron-hydrocarbon complex compounds
11/25/2009	CN101589055A Process for the preparation of an (Rp)-8-substituted cAMPS
11/25/2009	CN101589047A Cathepsin proteases inhibitors
11/25/2009	CN101589046A Azaspiro derivatives
11/25/2009	CN101589045A Imidazopyrazines as protein kinase inhibitors
11/25/2009	CN101589043A Purine derivatives
11/25/2009	CN101589042A Pharmacologically active n,n'-substituted 3,7-diazabicyclo [3.3.1] nonanes, pharmaceutical compositions based thereon and a method for the use thereof
11/25/2009	CN101589041A Nitrogen-containing heterocyclic compounds and methods of use thereof
11/25/2009	CN101589040A Polymorphic forms of a macrocyclic inhibitor of HCV
11/25/2009	CN101589039A Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase
11/25/2009	CN101589038A Heterocyclidene-N-(aryl)acetamide derivative
11/25/2009	CN101589037A Heteromonocyclic compound and use thereof
11/25/2009	CN101589036A Aminopyrimidines useful as inhibitors of protein kinases
11/25/2009	CN101589029A 1,2,3-triazole derivatives as sigma receptor inhibitors
11/25/2009	CN101589027A Process for the sulfinylation of a pyrazole derivative
11/25/2009	CN101589026A Method of treatment of glioma brain tumour
11/25/2009	CN101589025A Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors
11/25/2009	CN101589024A Novel minor groove binders
11/25/2009	CN101589023A Process for production of 1-hydroxy-19-norcyclovitamin D derivative and intermediate for the production

1 ... 2488 2489 2490 2491 2492 2493 2494 2495 2496 2497 2498 2499 2500 2501 2502 2503 2504 2505 2506 2507 2508 ... 7860